Butterfly Network, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a BFLY research report →
Range $10 – $15
Price Chart
About the company
Butterfly Network, Inc. functions as a digital health enterprise, specializing in the invention, production, and global commercialization of cutting-edge ultrasound imaging technologies for both domestic and international markets. The company's innovative product portfolio includes the portable Butterfly iQ, a versatile single-probe system capable of whole-body ultrasound imaging, and the Butterfly iQ+, a point-of-care ultrasound device engineered to connect effortlessly with smartphones, tablets, and existing hospital computer networks.
- CEO
- Joseph DeVivo
- IPO
- 2020
- Employees
- 220
- HQ
- Burlington, MA, US
Get TickerSpark's AI analysis on BFLY
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $1.44B
- P/E
- -29.04
- Fwd P/E
- 809.96
- PEG
- -0.65
- P/S
- 13.19
- P/B
- 8.78
- EV/EBITDA
- -33.42
- Div Yield
- 0.00%
- Gross Margin
- 70.26%
- Op Margin
- -49.16%
- Net Margin
- -43.56%
- ROE
- -28.22%
- ROIC
- -27.19%
Latest fiscal year · YoY change
- Revenue
- $97.61M+19.0%
- Gross Profit
- $45.73M-6.3%
- Op Income
- $-86,415,000
- Net Income
- $-77,064,000-6.3%
- EPS
- $-0.31+8.8%
- OCF Growth
- +69.5%
- FCF Growth
- +63.9%
- 52W High
- $10.21
- 52W Low
- $2.33
- 50D MA
- $7.56
- 200D MA
- $6.19
- Beta
- 2.12
- RSI (14)
- 41
- Avg Volume
- 5.08M
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
Butterfly delivered a strong Q3 with 52% revenue growth, record gross margin, and raised full-year guidance, while highlighting expanding enterprise, Embedded, and home-care opportunities.· October 29, 2026
- Q3 revenue was $32.6 million, up 52% year over year and 9% above the top end of guidance.
- Gross profit hit a company record at $23.8 million; adjusted gross margin rose to 73% from 64% a year ago.
- Adjusted EBITDA loss improved to $1.2 million from $8.1 million last year, and cash use fell to $2.4 million.
- Full-year 2026 guidance was raised: revenue to $123 million-$126 million and adjusted EBITDA loss to $12 million-$15 million.
- Management pointed to stronger enterprise POCUS, growing Embedded partnerships, FedRAMP authorization, and Home & Community Care launching in Q4.
Q3 2026 revenue was $32.6 million, up 52% year over year, and exceeded the top end of guidance by 9%. U.S. revenue was $27.5 million, up 71% year over year, while international revenue was $5.1 million, down 5%. Core POCUS revenue was $21.5 million, up 5%, and Butterfly Embedded revenue was $11.1 million, up over 1,000%. Gross profit was a record $23.8 million versus a prior-year gross loss of $3.8 million; excluding a prior-year $17.5 million write-down, gross profit would have been up $10.1 million or 74% year over year. Adjusted gross margin increased to 73% from 64%, and adjusted EBITDA loss improved to $1.2 million from $8.1 million. Cash and cash equivalents, excluding restricted cash, were $122 million, and cash use in the quarter was $2.4 million. For full-year 2026, the company raised revenue guidance to $123 million-$126 million and adjusted EBITDA loss guidance to $12 million-$15 million. That implies Q4 revenue of $31 million-$34 million and Q4 adjusted EBITDA loss of $3 million-$6 million.
Joseph DeVivo said the quarter showed Butterfly’s strategy is becoming more durable and compounding, with U.S. enterprise contracts, Embedded partnerships, and future home-care revenue all building the top line. He emphasized a sixfold increase in the Compass AI pipeline since its introduction, five seven-figure TCV deals and ten six-figure TCV deals in Q3, and FedRAMP authorization as a potential catalyst for federal business. His tone was highly optimistic about the roadmap, especially the upcoming P5.1 chip, Apollo, wearables, and the 2028 cart opportunity, while repeatedly framing the business as entering a new growth phase.
John Doherty focused on the financial strength of the quarter: revenue beat guidance, gross margin was the highest in company history, and adjusted EBITDA improved materially. He said the margin expansion was helped by a richer mix from Embedded and a tariff refund, and noted cash remained solid at $122 million with lower quarterly cash burn of $2.4 million. He also described the new S-3 shelf and ATM as proactive corporate housekeeping, stressing there is no immediate cash need and that any capital raised would be used only for high-ROI opportunities with dilution discipline.
Analysts focused heavily on Embedded revenue cadence, guidance conservatism, and the company’s ability to scale internationally. Management said Embedded remains lumpy quarter to quarter, but the underlying pipeline is growing, the business is trending above prior expectations, and they will only guide to signed business rather than speculate on future deals. On international, they acknowledged underinvestment versus the U.S. and said the plan is to apply the U.S. enterprise playbook abroad without requiring a massive step-up in spend. Questions on Home & Community Care centered on proof of cost savings and expansion beyond CHF, and management said the initial partner is focused on CHF but has interest in additional use cases; they also declined to quantify partner data for confidentiality reasons.
The call presented a broadening growth story: enterprise POCUS is gaining traction, Embedded is adding meaningful revenue and potential future royalty-like layers, and Home & Community Care is about to begin scanning with initial revenue expected in Q4. Management also highlighted FedRAMP, a growing government pipeline, and an upcoming next-gen chip that they believe can move Butterfly beyond image-quality parity and expand the addressable market.
International revenue declined 5% year over year, and management admitted the business has underperformed because it relied too much on distributors and lacked the U.S.-style enterprise infrastructure. Embedded revenue remains timing-dependent and lumpy, and management would not quantify Midjourney or give firm 2027 guidance yet. The ATM filing may also raise investor dilution concerns, even though management framed it as precautionary and said there is no immediate cash need.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 81.2%
- Shares Outstanding
- 267.46M
- Float Shares
- 217.19M
of shares held by institutions
264 13F filers
Buy/sell ratio 0.25. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Fmr LLC | 37.36M | ▲ 32.45M |
| Blackrock, Inc. | 19.07M | ▲ 248.25K |
| Glenview Capital Management, LLC | 14.34M | 0 |
| Hood River Capital Management LLC | 13.19M | ▲ 4.57M |
| Vanguard Group Inc | 11.32M | ▲ 275.89K |
| Vanguard Capital Management LLC | 9.25M | ▲ 693.96K |
| Fosun International Ltd | 7.40M | ▼ 2.84M |
| D. E. Shaw & Co., Inc. | 6.39M | ▲ 5.27M |
| State Street Corp | 5.92M | ▲ 153.23K |
| Geode Capital Management, LLC | 5.38M | ▲ 33.88K |
| Ark Investment Management LLC | 5.25M | ▲ 168.76K |
| Awm Investment Company, Inc. | 4.33M | ▼ 100.00K |
Held by 236 ETFs
Biggest fund positions in BFLY by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Nov 13, 26 | ROTHBERG JONATHAN M | sell | 359,382 |
| Nov 11, 26 | Doherty John N. | sell | 50,000 |
| Oct 30, 26 | DEVIVO JOSEPH | sell | 90,600 |
| Oct 13, 26 | NOONEN MICHAEL | other | 37,037 |
| Oct 9, 26 | NOONEN MICHAEL | other | 0 |
| Oct 6, 26 | DEVIVO JOSEPH | sell | 35,790 |
| Oct 2, 26 | Carlson Megan | sell | 10,114 |
| Sep 22, 26 | DEVIVO JOSEPH | sell | 2,811 |
| Sep 23, 26 | DEVIVO JOSEPH | sell | 3,169 |
| Sep 4, 26 | Cashman Steve | sell | 140,112 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our BFLY coverage
Recent articles, reports, and earnings notes.
No research on BFLY yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate BFLY report →Butterfly Network (NYSE:BFLY) Stock: Insider Jonathan Rothberg Sells 359,382 Shares
defenseworld.net · Nov 19
Butterfly Network to Present at 9th Annual Evercore Healthcare Conference on December 1, 2026
businesswire.com · Nov 17
Butterfly Network CEO Sees Chip Revenue Dwarfing Ultrasound Device Business
marketbeat.com · Nov 13
Butterfly Network, Inc. (BFLY) Presents at 2026 UBS Global Healthcare Conference Transcript
seekingalpha.com · Nov 10
Butterfly Network Q3 Earnings Call Highlights
marketbeat.com · Oct 30
Butterfly Network, Inc. (BFLY) Q3 2026 Earnings Call Transcript
seekingalpha.com · Oct 29
Butterfly Network, Inc. (BFLY) Reports Q3 Loss, Beats Revenue Estimates
zacks.com · Oct 29
Butterfly Network Reports Third Quarter 2026 Financial Results
businesswire.com · Oct 29
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.